Tumor lysis syndrome tls is an oncologic emergency that is usually seen when tumor cells undergo rapid decomposition spontaneously or, more often, in response to cytoreductive therapy with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. The new england journal of medicine n engl j med 376. Tumor lysis syndrome tls is a constellation of metabolic. Tumor lysis syndrome is a condition that tends to be precipitated after a cancer treatment. Tumor lysis syndrome tls is a condition in which the necrosis of large numbers of tumor cells causes the release of toxic amounts of intracellular contents into the circulation resulting in acute hyperuricemia, electrolyte abnormalities hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury aki. Tls can become lifethreatening if is not managed or treated. Tumor lysis syndrome tls is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and n it seems to us that you have your javascript disabled on your browser. Tumor lysis syndrome is a medical emergency that, without prompt intervention, can result in significant morbidity related to cardiac arrhythmias, seizures, renal failure, and possibly death. The tumor lysis syndrome is the most common diseaserelated emergency encountered by physicians caring for children or adults with hematologic cancers.
Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. The incidence varies on malignancy type, but is most common with hematologic neoplasms during cytotoxic treatment. Guidelines for the management of pediatric and adult tumor lysis syndrome. Tls is an oncologic emergency caused by the rapid and massive breakdown of tumor cells, either spontaneously or after the initiation of cytoreductive therapy. In the middle column of table 1 page 1846, the value for ionized calcium in the hypocalcemia row should have been tumor lysis syndrome in the current classification system of cairo and bishop,10 the tumor lysis syndrome can be classified as laboratory or clinical table 1. Aug 11, 2011 the patient was 55yearold black man with chronic lymphocytic leukemia in whom the tumor lysis syndrome developed after rituximab and bendamustine treatment despite saline and allopurinol prophylaxis. Tumor lysis syndrome tls is one of the metabolic oncologic emergencies identified by the oncology nursing society.
Tumor lysis syndrome tls in adult patients page 1 of 7. Laboratory tumor lysis syndrome requires that two or more of the following metabolic abnormalities occur within 3 days before or up to 7 days after the initiation. Tls commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. Common complications of tls include arrhythmias, which are caused by hypocalcemia or hyperkalemia, renal failures due to hyperuricemia or hyperphosphatemia, and.
Tumor lysis syndrome tls is a potentially fatal complication of induction therapy for several types of malignancies. Tumor lysis syndrome shouldnt be taken lightly for it can provide grave effects. Clinical journal of the american society of nephrology. Tumor lysis syndrome tls is a metabolic derangement that results from rapid destruction of cells. Tumour lysis syndrome in a patient with renalcell carcinoma treated with sunitinib malate. Tumor lysis syndrome with acute uric acid nephropathy may occur spon taneously. Its incidence in solid tumors is rare, but has a high mortality rate owing to the lack of prophylactic therapy to prevent this. It commonly occurs in hematological malignant patients particularly nonhodgkins lymphoma and acute leukemia due to chemotherapy or spontaneously. Tumor lysis syndrome tls is an oncologic emergency from the intracellular release of material in lysing malignant cells. Pdf tumor lysis syndrome in patients with hematological. We would like to report an additional case recently seen in our facility. Tumor lysis syndrome tls is an oncologic emergency with a constellation of laboratory findings that result from the lysis of cancer cells. In cases of solid tumors, tls usually occurs spontaneously and after the initiation of anticancer therapy, and it has a high mortality rate.
Tumor lysis syndrome tls, a potential complication of cancer treatment, occurs when malignant cells quickly lyse, or break open, and the internal contents of. A case of spontaneous tumor lysis syndrome in a patient with. Blood sampling for pharmacokinetic studies was performed before and 2, 3, 4, 6, and 8 hours the new england journal of medicine. Tumor lysis syndrome an overview sciencedirect topics. Dying cells release large amounts of potassium, phosphate, and uric acid into the blood. Nejm resident 360 is a product of nejm group, a division of the massachusetts medical.
Guidelines for the management of hyperkalemia in adults, sep 2015. Tumor lysis syndrome in patients with hematological malignancies article pdf available in journal of oncology 20173. It is characterized by hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemia. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with shortcourse, highdose cytosine arabinoside, cisplatin, and etoposide. Tumor lysis syndrome tls is a potentially lifethreatening emergency that can develop rapidly after the release of intracellular contents from lysed malignant cells. Tumor lysis syndrome is characterized by hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia resulting from rapid tumor cell death. Within 6 hours after receiving rasburicase at a dose of 0. Catabolism of these nucleic acids into uric acid leads to hyperuricemia 1,2,11. This can cause heart or kidney problems and lead to kidney failure.
Tumor lysis syndrome tls was first described in 1929 by bedrna and polcak in patients with chronic leukemia. Tumor lysis syndrome tls is a potentially lifethreating complication of tumors or chemotherapy treatment. The earlier it is treated, the less likely it is to be harmful to an individual and spread through the body. Control of plasma uric acid in adults at risk for tumor lysis syndrome.
Tumor lysis syndrome in small cell lung cancer springerlink. Tumor lysis syndrome tls is a potentially fatal complication in patients with large, rapidly proliferating tumor cell cancers that may occur after chemotherapy. This algorithm has been developed for md anderson using a multidisciplinary approach considering circumstances particular to md andersons specific patient population, services and structure, and clinical information. Tumor lysis syndrome american society of nephrology. This condition is a group of symptoms and a complication from cancer treatment. Tumor lysis syndrome tls is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of. Managing tumor lysis syndrome in the era of novel cancer. Correspondence from the new england journal of medicine the tumor lysis syndrome.
Tumor lysis syndrome tls is a lifethreatening oncologic emergency that occurs when cancer cells break down, either spontaneously or after initiation of cytotoxic chemotherapy, and release their intracellular contents into the bloodstream. Tumor lysis syndrome is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer, where large amounts of tumor cells are killed off at the same time by the treatment, releasing their contents into the bloodstream. Correction from the new england journal of medicine the tumor lysis syndrome. The tumor lysis syndrome is the most common diseaserelated emergency. Tumor lysis syndrome is an oncometabolic emergency resulting from rapid cell death. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome. Berns tumor lysis syndrome tls is an oncologic emergency triggered by the rapid release of intracellular material from lysing ma.
The tumor lysis syndrome is the most common diseaserelated emergency in children and adults with hematologic cancers. The advent of novel and targeted therapies that have improved tumor killing efficacy has the potential to increase the risk of tls when used as part of frontline therapy. Tumor lysis syndrome tls is an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation. Impact of dialysis requirement on outcomes in tumor lysis. Tumor lysis syndrome tls is a life threatening emergency due to destruction and massive release of intracellular metabolites from cancer cells often resulting in acute kidney injury aki, sometimes severe enough to require dialysis aki. Supported in part by grants ca21765 and u01 gm92666 from the. Hematologic malignancies strongly associated with tumor lysis syndrome eg. Tumor lysis syndrome is a rare case that may happen rapidly or spontaneously. Tumour lysis syndrome tls describes the metabolic derangements that occur with tumour breakdown following the initiation of cytotoxic therapy. Risk and prevention strategies can help avert tumor lysis syndrome. Tumor lysis syndrome tls is a metabolic complication of rapid cell turnover and therefore is seen most frequently in pediatric oncology patients with large tumor burdens often with renal parenchymal involvement, tumors with short doubling times and those exquisitely sensitive to cytotoxic therapy such as acute lymphoblastic leukemia all and nonhodgkin lymphoma nhl. Guidelines for the management of pediatric and adult tumor. Tumor lysis syndrome background tumor lysis syndrome tls in pediatric patients is an oncologic emergency that involves complications of hematologic or solid malignancies.
Cancer cells killed by therapy treatment may spill intracellular contents which may then accumulate faster than eliminated causing electrolyte and metabolic disturbances resulting to tumor lysis syndrome. Cne article prevention of tumor lysis syndrome in an. Supported in part by grants ca21765 and u01 gm92666 from the national institutes of health and by. Tumor lysis syndrome tls describes the clinical and laboratory. Tumor lysis syndrome, resulting from the abrupt release of intracellular ions into the blood stream due to sudden tumor cell death, is a serious complication of chemotherapy treatment. This occurs most commonly after the treatment of lymphomas and leukemias.
Usually occurs in patients with bulky, rapidly proliferating, and. The introduction of moreaggressive chemotherapy in the management of hematologic malignancies, and the rare appearance of the syndrome in some solid tumors such as renal cell carcinoma, nicholaou t, wong r, davis id. Tumor lysis syndrome epidemiology bmj best practice. Tumor lysis syndrome tumor mass effect late effects of cancer treatment adolescentsyoung adults with cancer. The shift of potassium, phosphorus, and nucleic acid material into the extracellular space can rapidly overcome existing homeostatic mechanisms, leading to acute kidney failure, arrhythmia, and death. Current understanding of tumor lysis syndrome rahmani. Tumor lysis syndrome in patients with acute myeloid leukemia. All the study patients provided written informed consent. Tumor lysis syndrome tumor mass effect late effects of cancer treatment adolescentsyoung adults with cancer welcome. Tumor lysis syndrome symptoms, causes, guidelines and treatment.
Tumor lysis syndrome is a common complication resulting from treatment of bloodborne malignancies such as acute lymphocytic leukemia and highgrade nonhodgkins lymphoma. Classically, tumor lysis is associated with cytotoxic chemotherapy, including. Tumor lysis syndrome after radiofrequency ablation of. This syndrome occurs more frequently in hematologic malignancies and lymphomas. The patient was 55yearold black man with chronic lymphocytic leukemia in whom the tumor lysis syndrome developed after rituximab and bendamustine treatment despite saline and allopurinol prophylaxis. Cairobishop definition of laboratory tumor lysis syndrome and clinical tumor lysis syndrome. Guidelines for the management of tumour lysis syndrome in. May 04, 2015 tumor lysis syndrome is an oncometabolic emergency resulting from rapid cell death. Most common in rapidly growing hematologic malignancies, tls. Journal of clinical oncology, 2827, 420742 larson, r.
Clinicians should stratify every hospitalized cancer patient and especially those receiving chemotherapy for the risk of tumor lysis syndrome. Standardized guidelines, however, are needed to aid in the stratification of patients according to risk and to establish prophylaxis and treatment recommendations for patients at risk or with established tls. This is typically seen in hematologic cancers, but can be seen more rarely in solid tumor diseases. Purpose tumor lysis syndrome tls has recently been subclassified into either laboratory tls or clinical tls, and a grading system has been established. In the middle column of table 1 page 1846, the value for ionized calcium in the hypocalcemia row should have been tumor lysis syndrome. When cancer cells break down quickly in the body, levels of uric acid, potassium, and phosphorus rise faster than the kidneys can remove them. The new england journal of medicine n engl j med 378.
Study treatment patients were assigned sequentially to doseesca lation groups of three patients or more accordthe new england journal of medicine downloaded from nejm. Tumor lysis syndrome tls describes the pathological sequela of the rapid lysis of tumor cells. Tumor lysis syndrome tls in adult patients page 1 of 7 disclaimer. Tumor lysis syndrome hematology jama oncology jama. Patients with tls are complicated to treat and often have an unpredictable trajectory. Tumor lysis syndrome definition of tumor lysis syndrome by. It happens frequently in cancers receiving chemotherapy, particularly hematological malignancies.
Tumor lysis syndrome tls is a known complication of malignancy and its treatment. Although much of the treatment for cancer occurs in the outpatient setting, patients are often admitted because of complications from their primary disease or from the cancer treatment. Tumor lysis syndrome that leads to acute renal failure requiring dialysis andor icu admission can be associated with a higher rate of. The tumor lysis syndrome is the most common diseaserelated emergency in. Tumor lysis syndrome tls is an oncologic emergency caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into systemic circulation. Tumor lysis syndrome american academy of pediatrics. The patient was a 55yearold black man with chronic lymphocytic leukemia in whom the tumor lysis syndrome developed after rituximab and bendamustine treatment despite saline and allopurinol prophylaxis. Tumor destruction may be due to spontaneous or treatmentrelated causes, resulting in electrolyte and metabolic imbalances. Highrisk features for tumor lysis syndrome include the followingref9. Current understanding of tumor lysis syndrome read by qxmd. Electrolyte derangements and even downstream complications may also occur prior to the initial presentation to a medical provider, before an oncologic diagnosis has been established. When clearance of these products, by excretion renal or hepatic excretion or phagocytosis by the reticuloendothelial system 23, is impaired and their serum burden increases, the clinical sequelae of tls may occur. Tumor lysis syndrome tls is an oncologic emergency triggered by the rapid release of intracellular material from lysing malignant cells. Tumor lysis syndrome tls is a serious, sometimes lifethreatening oncologic emergency caused by rapid and massive cellular lysis and subsequent release of tumor cell contents and cytokines into.
The patient was a 55yearold black man with chronic lymphocytic leukemia in whom the tumor lysis syndrome developed after rituximab and bendamustine treatment despite saline and allopurinol. Tls is a direct consequence of cell lysis and release of intracellular products. Apr 15, 2015 first described by bedrna and polcak in patients with chronic leukaemia treated with radiotherapy, tumour lysis syndrome tls is a metabolic syndrome caused by the breakdown of malignant cells. Children and adolescents with cancer are often managed in the inpatient setting at the time of diagnosis.
In oncology and hematology, this is a potentially fatal complication. Tumor lysis syndrome in patients with hematological. What are the risk factors for tumor lysis syndrome tls. Tumor lysis syndrome discharge care what you need to know. Journal of clinical pharmacy and therapeutics, 38, 308. Tls results from the rapid destruction of malignant cells and the abrupt release of intracellular ions, nucleic acids, proteins and their metabolites into the extracellular space. The impact of dialysis requirement in aki has not been explored.
488 1092 53 1115 906 661 664 62 515 309 520 1276 1112 1328 147 858 257 308 179 581 1100 934 1084 176 1116 351 1480 522 960 1493 1072 359 1190 1481 718